- Severe disorders with devastating and life-threatening medical consequences
- Disorders with ineffective, or no treatment options
- Disorders that are ultra-rare and affect very small numbers of patients
The big bounce in Biogen's valuation over the past month would likely bake in a good chunk of the upside premium that could come from any takeover offer.
Alexion Pharmaceuticals (ALXN) stock was initiated with an "outperform" rating at RBC Captial earlier today as the firm expects the company 'to continue to dominate the rare disease space.'